JP5547637B2 - 浮腫を治療または軽減するための新規な化合物およびその使用方法 - Google Patents

浮腫を治療または軽減するための新規な化合物およびその使用方法 Download PDF

Info

Publication number
JP5547637B2
JP5547637B2 JP2010527904A JP2010527904A JP5547637B2 JP 5547637 B2 JP5547637 B2 JP 5547637B2 JP 2010527904 A JP2010527904 A JP 2010527904A JP 2010527904 A JP2010527904 A JP 2010527904A JP 5547637 B2 JP5547637 B2 JP 5547637B2
Authority
JP
Japan
Prior art keywords
edema
oligonucleotide compound
oligonucleotide
treatment
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010527904A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539974A (ja
JP2010539974A5 (cg-RX-API-DMAC7.html
Inventor
ザルガリ，アレゾウ
アクセレッソン，ラース−ヨラン
スピーク，アン−クリスティン
コウズネットソフ，ニコライ
Original Assignee
インデックス・ファーマシューティカルズ・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インデックス・ファーマシューティカルズ・アクチエボラーグ filed Critical インデックス・ファーマシューティカルズ・アクチエボラーグ
Publication of JP2010539974A publication Critical patent/JP2010539974A/ja
Publication of JP2010539974A5 publication Critical patent/JP2010539974A5/ja
Application granted granted Critical
Publication of JP5547637B2 publication Critical patent/JP5547637B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
JP2010527904A 2007-10-05 2008-10-02 浮腫を治療または軽減するための新規な化合物およびその使用方法 Expired - Fee Related JP5547637B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97801007P 2007-10-05 2007-10-05
US60/978,010 2007-10-05
PCT/SE2008/000542 WO2009045145A1 (en) 2007-10-05 2008-10-02 Novel compounds for the treatment or alleviation of edema, and methods for their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014101486A Division JP5914567B2 (ja) 2007-10-05 2014-05-15 浮腫を治療または軽減するための新規な化合物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2010539974A JP2010539974A (ja) 2010-12-24
JP2010539974A5 JP2010539974A5 (cg-RX-API-DMAC7.html) 2011-11-10
JP5547637B2 true JP5547637B2 (ja) 2014-07-16

Family

ID=40526448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010527904A Expired - Fee Related JP5547637B2 (ja) 2007-10-05 2008-10-02 浮腫を治療または軽減するための新規な化合物およびその使用方法
JP2014101486A Expired - Fee Related JP5914567B2 (ja) 2007-10-05 2014-05-15 浮腫を治療または軽減するための新規な化合物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014101486A Expired - Fee Related JP5914567B2 (ja) 2007-10-05 2014-05-15 浮腫を治療または軽減するための新規な化合物およびその使用方法

Country Status (7)

Country Link
US (1) US8410068B2 (cg-RX-API-DMAC7.html)
EP (2) EP2207555B1 (cg-RX-API-DMAC7.html)
JP (2) JP5547637B2 (cg-RX-API-DMAC7.html)
CA (1) CA2738070C (cg-RX-API-DMAC7.html)
DK (1) DK2656850T3 (cg-RX-API-DMAC7.html)
ES (1) ES2600919T3 (cg-RX-API-DMAC7.html)
WO (1) WO2009045145A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2573176T3 (en) * 2007-05-04 2016-08-01 Index Pharmaceuticals Ab Tumor growth retardant compounds and methods of use thereof
JP2011524899A (ja) * 2008-06-18 2011-09-08 インデックス・ファーマシューティカルズ・アクチエボラーグ がんの併用療法
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
DK2350283T3 (en) 2008-11-04 2016-02-01 Index Pharmaceuticals Ab RELATIONS AND PROCEDURES FOR THE TREATMENT OF INFLAMMATORY DISEASES IN THE CENTRAL NERVOUS SYSTEM
WO2012084996A2 (en) * 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Methods for identifying biologically active oligonucleotides capable of modulating the immune system
WO2012084991A1 (en) * 2010-12-21 2012-06-28 Index Pharmaceuticals Ab Biologically active oligonucleotides capable of modulating the immune system ii
PL2731597T3 (pl) * 2011-07-12 2024-04-29 Vanderbilt University Sposoby leczenia stanu zapalnego i nadciśnienia tętniczego za pomocą wychwytywaczy gamma-ketoaldehydowych
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610289A (en) * 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US7517644B1 (en) * 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
DE69232722T2 (de) * 1991-08-23 2002-12-05 The Board Of Regents Of The University Of Nebraska, Lincoln Verfahren und zusammensetzungen für zelluläre reprogrammierung
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
AU2001284790A1 (en) * 2000-08-09 2002-02-18 Mount Sinai School Of Medicine Kruppel-like factor 6 (klf6), a tumorsuppressor protein, and dia gnostics, therapeutics, and screening based on this protein
US7630836B2 (en) 2001-05-30 2009-12-08 The Kitasato Institute Polynucleotides
WO2004080148A2 (en) 2002-10-02 2004-09-23 Nuvelo, Inc. Novel nucleic acids and polypeptides
JP2006502722A (ja) * 2002-10-15 2006-01-26 ノバルティス アクチエンゲゼルシャフト 薬物処置の副作用としての浮腫を予測する方法
JP2004166699A (ja) * 2002-11-06 2004-06-17 Takeda Chem Ind Ltd 抗利尿剤
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2005033284A2 (en) * 2003-10-01 2005-04-14 The Regents Of The University Of California Compositions and methods for gene expression
US7374927B2 (en) * 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
PL2179737T3 (pl) 2005-07-01 2014-01-31 Index Pharmaceuticals Ab Sposób do modulowania wrażliwości na steroidy
EP1912633A4 (en) * 2005-08-09 2009-10-21 Univ Virginia METHODS AND COMPOSITIONS FOR INHIBITING VASCULAR PERMEABILITY
DK2573176T3 (en) 2007-05-04 2016-08-01 Index Pharmaceuticals Ab Tumor growth retardant compounds and methods of use thereof

Also Published As

Publication number Publication date
US8410068B2 (en) 2013-04-02
EP2656850A3 (en) 2014-02-12
EP2207555A1 (en) 2010-07-21
DK2656850T3 (en) 2016-11-28
EP2207555A4 (en) 2010-11-24
EP2656850B1 (en) 2016-07-27
US20100240736A1 (en) 2010-09-23
CA2738070C (en) 2018-03-20
JP2010539974A (ja) 2010-12-24
EP2656850A2 (en) 2013-10-30
JP5914567B2 (ja) 2016-05-11
JP2014204722A (ja) 2014-10-30
CA2738070A1 (en) 2009-04-09
WO2009045145A1 (en) 2009-04-09
ES2600919T3 (es) 2017-02-13
EP2207555B1 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
JP5914567B2 (ja) 浮腫を治療または軽減するための新規な化合物およびその使用方法
JP2018203747A5 (cg-RX-API-DMAC7.html)
CN110461862A (zh) 用于治疗由衰老细胞介导的病症和用于治疗癌症的基于肽的蛋白酶体抑制剂
ES2673209T3 (es) Procedimientos de tratamiento del cáncer colorrectal
ES2464731T3 (es) Compuestos y procedimientos para reducir el reclutamiento y/o migración de células polimorfonucleares
CN110564842B (zh) 细胞色素酶cyp26a1在制备治疗神经病理性疼痛的药物中的应用
CN104083761A (zh) microRNA-101抑制剂在制备预防或治疗骨关节炎药物中的应用
JPWO2014157380A1 (ja) 創傷または線維症の治療剤
CN104958286B (zh) 用于治疗疾病的化合物
US11865133B2 (en) Pharmaceutical composition comprising organoid and anti-inflammatory agent for preventing or treating inflammatory bowel disease
CA3043103C (en) Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
CN115381950B (zh) Rab 35或其下游调控分子在治疗骨折后慢性疼痛中的应用
US20180086827A1 (en) Therapeutics and methods of treating fibroproliferative diseases
Benardeau et al. The Novel Soluble Guanylyl Cyclase (sGC) Activator Runcaciguat Induced Renal Vasodilation and Reduced Kidney Damage in a Rat CKD Model: PO0600
Chen et al. Histone Deacetylase 6 Inhibition Mitigates Renal Fibrosis by Suppressing TGF-β/SMAD3 and eGFR Signaling Pathways: PO0602
JP2025532680A (ja) 抗線維化マイクロｒｎａ組成物
JP5910299B2 (ja) 炎症性関節疾患治療薬
Jiao et al. Crucial Role of STAT6 Signaling in Renal Fibrosis: PO0603
Mori et al. Inhibition of KIM-1-Mediated Fatty Acid Uptake by a Novel Inhibitor Attenuates Pro-Fibrotic Responses in Multiple Models of Human Primary Kidney Epithelial Cells Including Kidney Tubuloids: PO0601
CN121065177A (zh) 一种靶向ASGR1的siRNA、递送系统及其应用
CN106999555A (zh) 用于治疗癌症的新型组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140515

R150 Certificate of patent or registration of utility model

Ref document number: 5547637

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees